Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 607 participants.

Also called NCT01734785

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 607 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01734785
  • EudraCT 2012-002270-31
Other papers using this trial's data
  • Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial Diabetes care, 2017-02 DOI, PubMed 27913576

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Brazil, Canada, El Salvador, France, New Zealand, Norway, South Korea, Spain, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01734785. Randomized; double masking; primary purpose treatment. Start 2013-02-08 (actual); primary completion 2015-03-23 (actual). Results posted on 2016-04-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Linagliptin
Intervention (Drug)
Empagliflozin + Linagliptin
Intervention (Drug)
Empagliflozin + Linagliptin
Intervention (Drug)
Empagliflozin + Linagliptin
Intervention (Drug)
Empagliflozin placebo + Linagliptin placebo
Intervention (Drug)
Empagliflozin + Linagliptin
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01734785
Content hash
090f61256c491add15ae3ae6faa25365f02706244c743b3cf8a0a9bc3518922c